1. 111 MUTATIONAL PROFILE AND KARYOTYPIC ABNORMALITIES OF CLINICAL TRIAL PATIENTS WITH HIGHER-RISK MDS FOLLOWING FAILURE OF HYPOMETHYLATING AGENTS (HMAS): IMPACT ON RESPONSE TO RIGOSERTIB THERAPY. (April 2015) Authors: Mufti, G.J.; Best, S.; Lea, N.; Hellstrom-Lindberg, E.; Silverman, L.R.; Garcia-Manero, G.; Azarnia, N.; Petrone, M.E.; Snyder, B.R.; Gohring, G. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS). (April 2015) Authors: Garcia-Manero, G.; Fenaux, P.; Al-Kali, A.; Baer, M.R.; Sekeres, M.; Roboz, G.; Gaidano, G.; Scott, B.; Greenberg, P.; Platzbecker, U.; Steensma, D.P.; Kambhampati, S.; Kreuzer, K.A.; Godley, L.; Collins, R.; Atallah, E.; Azarnia, N.; Petrone, M.E.; Snyder, B.R.; Maniar, M. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 88 BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION?. (April 2015) Authors: Silverman, L.R.; Fenaux, P.; Al-Kali, A.; Baer, M.R.; Sekeres, M.; Roboz, G.; Gaidano, G.; Scott, B.; Greenberg, P.; Platzbecker, U.; Steensma, D.P.; Kambhampati, S.; Kreuzer, K.A.; Godley, L.; Collins, R.; Atallah, E.; Navada, S.C.; Azarnia, N.; Garcia-Manero, G. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 89 A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML). Issue 1 (April 2015) Authors: Navada, S.C.; Garcia-Manero, G.; Hearn, K.; Odchimar-Reissig, R.; Demakos, E.; Alvarado, Y.; Daver, N.; DiNardo, C.; Konopleva, M.; Borthakur, G.; Azarnia, N.; Silverman, L.R. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S45 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in MDS Patients Treated with Rigosertib Versus Best Supportive Care (BSC). (April 2017) Authors: Nazha, A.; Sekeres, M.; Komrokji, R.; Steensma, D.; Kantarjian, H.; Roboz, G.; Fenaux, P.; Prebet, T.; Azarnia, N.; Zbyszewski, P.; Fruchtman, S.; Santini, V.; Silverman, L.; Platzbecker, U.; Garcia-Manero, G. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗